Cancer Causing Virus
Cancer Causing Virus - Related Videos
02:52
Harvesting Hepatitis E Virus Particles from Human Liver Cancer Cells
0 Views •
2026
Source: Meister, T. L., et al. A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks. J. Vis. Exp. (2020).This video demonstrates the process of isolating hepatitis E virus (HEV) particles from transfected human hepatocellular carcinoma cells. Extracellular viral particles are collected from filtered supernatants, while intracellular particles are released by subjecting the cells to repeated freeze-thaw cycles. The lysate is centrifuged, and the supernatant containing HEV...
01:03
Rous Sarcoma Virus (RSV) and Cancer
0 Views •
2023
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans. RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03
Rous Sarcoma Virus (RSV) and Cancer
0 Views •
2023
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans. RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
19:02
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
0 Views •
Cited by 30 •
2011
In this article, we describe the identification of the adeno-associated virus serotype 3 (AAV3) as the most efficient vector for targeting human liver cancer cells.
03:43
Virus Plaque Assay: A Technique to Measure Infectious Herpes Simplex Virus via Quantification of Plaques Formed in Monolayer of Virus-Infected Cells
0 Views •
2025
This video describes the virus plaque assay of the infectious herpes simplex virus or HSV. The diluted viral particles are inoculated to the monolayer of epithelial cells. Upon incubation, the virus forms plaques and is counted visually to determine the infectious virus titer.
FAQs
Viral infection can promote cancer when it alters the balance between cell growth and cell survival. Viral genes may redirect host-cell behavior, while viral proteins can interfere with tumor-suppressor pathways, which normally restrain abnormal proliferation. These changes matter because they connect an infection to malignant transformation rather than treating cancer as an isolated failure of cellular regulation.
When viral genetic material integrates into the host genome, it can permanently place virus-derived information within a cell’s genetic context. This event is distinct from temporary viral activity because the altered genetic material may continue influencing host-cell behavior after infection is established. In biology, integration provides a mechanism for studying how infection can produce durable changes associated with malignant transformation.
Persistent inflammation matters because it can sustain tissue damage alongside the infection. Unlike a mechanism centered on a single viral gene or protein, this process emphasizes the continuing interaction between the virus and its tissue environment. Studying that interaction helps biologists consider how infection-related injury may contribute to cancer development and why long-term infection is an important research concern.
Comparing human papillomavirus, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus broadens the biological picture beyond one viral model. Each example helps researchers examine how viral genes, interfering proteins, genome integration, persistent inflammation, or tissue damage may participate in cancer development. This comparative approach supports more general explanations of infection-associated malignancy.
Screening and vaccination address different points in the infection-to-cancer pathway. Screening strategies can support the identification of virus-associated cancer risk, while vaccination aims to reduce infection-related risk before malignant changes develop. Their study is important in biology and medicine because it links knowledge of viral mechanisms with approaches designed to prevent or detect cancer earlier.
Research on cancer-causing viruses can inform two complementary treatment directions. Antiviral therapies are investigated in relation to the infection that contributes to cancer, while targeted cancer therapies are studied in relation to the cellular changes associated with malignant transformation. Understanding viral genes, tumor-suppressor interference, integration, and inflammation helps connect biological mechanisms with therapeutic research.